Comments to the letter to the editor by Dr Sweta Subhadarshani

Abstract

Linked article: S. Subhadarshani et al. J Eur Acad Dermatol Venereol 2020; 34: e72–e73. https://doi.org/10.1111/jdv.15948.

A New Era with the Development of Cytokine-Based Therapy for Pruritus

“…The efficacy of antipruritic therapies targeting cytokinemediated signals has also been demonstrated in other chronic pruritic skin disorders, such as prurigo nodularis. Although dupilumab is FDA-approved for the treatment of moderate-to-severe AD, the antipruritus effect of dupilumab on prurigo nodularis has been demonstrated in observational studies (Beck et al, 2019;Giura et al, 2020;Naafs and Alemu Belachew, 2020). Currently, dupilumab is being tested for prurigo nodularis in a phase 3 clinical study (PRIME) (ClinicalTrials.gov identifier: NCT 04183335).…”